Global Ganja Report

It's been a week since Senate Majority leader Chuck Schumer of New York, joined by Sen. Cory Booker (D-NJ) and Sen. Ron Wyden (D-OR), unveiled much-anticipated draft legislation to legalize cannabis at the federal level, calling it a "long overdue" move "to right the wrongs of the failed war on drugs." The proposed Cannabis Administration & Opportunity Act would remove the plant from the Controlled Substances Act, and allow states to craft their own cannabis policies as they do with alcohol. It would also create a federal regulatory framework and impose an excise tax for cannabis products. It includes measures that would expunge prior convictions and allow those serving time for applicable crimes to petition for resentencing.

Two years and counting after Mexico’s Supreme Court ordered the country’s Congress to legalize cannabis, the high court justices ran out of patience with the legislative paralysis and issued a new ruling — this one removing penalties for personal use by judicial decree.

But there is no provision for commercial production, and the decree calls for tight federal regulation even of personal possession and cultivation. Will this move prove to be at least a beginning in the daunting challenge of ending Mexico’s long and bloody narco-nightmare?

The sex scandal investigation of Florida's far-right Rep. Matt Gaetz interlocks with a controversy concerning favoritism in handing out medical marijuana licenses in the Sunshine State. And one of the key beneficiaries appears to be Trulieve, now one of the leading cannabis companies in the United States. The origins of the firm go back to a nexus of prominent state Republicans, including names currently making stomach-churning national headlines.

Even as the edifice of cannabis prohibition crumbles state by state, the federal illegality of the plant and its psychoactive compound THC continues to drive a quest for loopholes in the relevant statutes.


The latest such legal artifice concerns Delta-8 tetrahydrocannabinol — a less potent cannabinoid than the more common and notorious Delta-9 THC. Is there truth to the claim that hemp-derived Delta-8 THC was inadvertently legalized by the 2018 Farm Bill?

Veteran war photographer Teun Voeten has worked in conflict zones from Afghanistan and Iraq to Rwanda and Sierra Leone, to Haiti, Nicaragua and Colombia. Now he makes the leap into academia, with his newly published doctoral thesis, Mexican Drug Violence: Hybrid Warfare, Predatory Capitalism and the Logic of Cruelty. Voeten attempts to provide a theoretical framework for the unrelenting cartel wars that may now threaten an actual collapse of the government in the United States' southern neighbor.

Progressives coast to coast breathed a heavy sigh of relief as Joe Biden took the oath of office, ending the turbulent and reactionary rule of Donald Trump over the past four years.

But hemp cultivation, like the rewriting and replacement of NAFTA, was one of the few areas that actually saw positive change in the Trump years—with bipartisan support. The 2018 Farm Bill that re-legalized the crop after generations of prohibition bore Trump’s signature.

And there are fears that Biden could mean a return to the Washington consensus of a corporate-friendly “free trade” status quo ante, shorn even of the limited populist measures of the Trump era.

For small farmers, including some hemp cultivators, Biden’s choice to lead the US Department of Agriculture (USDA) may provide a case in point.

Lebanon, long the Middle East's heartland of hashish, has legalized cannabis cultivation for the medical market—but before the law has even taken effect, rumblings of cynicism are heard from the country's traditional growers. The outlaw growers in the Bekaa Valley, with its centuries-long tradition of hash production, will likely remain illicit and face continued militarized enforcement—while corporate producers with state-of-the-art greenhouses on the urbanized coast dominate the industry. And the hashish market has been hard hit by the country's deep economic crisis, leaving the Bekaa cannabis farmers struggling.

In the near future, the CBD, THC or other cannabinoids you consume in edibles or medications may not be derived from cannabis at all, but grown in a laboratory.

Kevin Chen, CEO and co-founder of Hyasynth Bio, describes the Montreal-based start-up as "focused on engineering strains of yeast to produce the active compounds of cannabis without having to grow plants."